

Serial No. 08/482,283
Attorney Docket No. 4189.0083-06000

*Al
conced*

36. A composition of claim 35, wherein said TNF inhibitor is selected from the group consisting of a 30 kDa TNF inhibitor, a 40 kDa TNF inhibitor, a Δ 51 TNF inhibitor, and a Δ 53 TNF inhibitor.--

REMARKS

Applicants request entry of the above-noted amendments prior to examination of this application. This application incorporates by reference U.S. Patent Application Serial No. 07/555,274, filed July 19, 1990 (the '274 application). See, e.g., the present specification at page 1, first paragraph. The drawing figures 1 to 45 added above are incorporated from the '274 application. New claims 2-9 and 14-16 are also fully supported by the '274 application, the disclosure of which is included by reference in the present specification.

This application also incorporates by reference U.S. Patent Application Serial No. 07/506,522, filed on April 6, 1990, which issued as U.S. Patent No. 5,075,222 (the '222 patent) on December 24, 1991. See, e.g., the present specification at page 1, first paragraph. New claims 17 and 22-25 are fully supported by the '222 patent, the disclosure of which is included by reference in this specification.

Claims 10-13, 18-21, and 26-36 are also fully supported by the present specification.


Serial No. 08/482,283
Attorney Docket No. 4189.0083-06000

Applicants request entry of the above-noted amendments prior to examination of this application.

If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
M. Paul Barker
Reg. No. 32,013

Date: January 30, 1997